Study identifier:D9617C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy of esomeprazole 40 mg once daily versus placebo or esomeprazole 20 mg once daily versus placebo in prevention of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs
NSAIDs
Phase 3
No
Esomeprazole
All
276
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess theefficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.
Location
Location
Five Dock, NSW, Australia
Location
Various Cities, NSW, Australia
Location
Carina Heights, QLD, Australia
Location
Kippa Ring, QLD, Australia
Location
Various Cities, SA, Australia
Location
Various Cities, Tasmania, Australia
Location
Ivanhoe, VIC, Australia
Location
Various Cities, VIC, Australia
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.